AI startup Nucleai has immuno-oncology treatment failures in its sights

AI startup Nucleai has immuno-oncology treatment failures in its sights

Source: 
Pharmaforum
snippet: 

Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker Debiopharm.